Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Duration: November 1, 2007
to
present
General Issues: Medicare/Medicaid , Pharmacy , Health Issues , Budget/Appropriations , Alcohol & Drug Abuse , Government Issues , Labor Issues/Antitrust/Workplace , Copyright/Patent/Trademark , Medical/Disease Research/Clinical Labs
Spending: about $8,761,270 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Agency for Healthcare Research & Quality (AHRQ), Federal Trade Commission (FTC), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Management & Budget (OMB), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on May 2.
Original Filing: 301577720.xml
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 31.
Original Filing: 301542513.xml
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Nov. 14, 2023.
Original Filing: 301518766.xml
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Aug. 1, 2023.
Original Filing: 301494032.xml
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 26, 2023.
Original Filing: 301469241.xml
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics
Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes.
Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 31, 2023.
Original Filing: 301445398.xml
Lobbying Issues
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics
HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics
HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301410544.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
H.R. 7008 - Pre-approval information exchange act of 2022 - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
H.R. 7667 - PDUFA Reauthorization - lobbying for the inclusion of HR 7008 in HR 7667 and passage.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Aug. 1, 2022.
Original Filing: 301397912.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
H.R. 7008 - Pre-approval information exchange act of 2022 - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
H.R. 7667 - PDUFA Reauthorization - lobbying for the inclusion of HR 7008 in HR 7667 and passage.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 12, 2022.
Original Filing: 301345164.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 27, 2022.
Original Filing: 301339997.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Nov. 1, 2021.
Original Filing: 301316706.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 15, 2021.
Original Filing: 301276436.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
PN 124 - Nomination of Chiquita Brooks-LaSure to be Administrator of the Centers for Medicare and Medicaid Services.
H.R.1319 - American Rescue Plan Act of 2021 - This bill provides additional relief to address the continued impact of COVID-19 (i.e., coronavirus disease 2019) on the economy, public health, state and local governments, individuals, and businesses.
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
Agencies Lobbied
U.S. Senate
Lobbying Issues
Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs.
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans.
S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D.
S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 21, 2021.
Original Filing: 301268630.xml
Lobbying Issues
HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021.
PN 124 - Nomination of Chiquita Brooks-LaSure to be Administrator of the Centers for Medicare and Medicaid Services.
H.R.1319 - American Rescue Plan Act of 2021 - This bill provides additional relief to address the continued impact of COVID-19 (i.e., coronavirus disease 2019) on the economy, public health, state and local governments, individuals, and businesses.
Agencies Lobbied
U.S. Senate
Lobbying Issues
We have not lobbied on any specific introduced legislation this quarter. Lobbying contacts have been related to the possible introduction of a bill to codify FDA guidance allowing for the exchange of certain economic and clinical data for a drug or new drug use while the product is under review for approval at FDA.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 31, 2021.
Original Filing: 301247276.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization, COVID-19
H.R. 3, Lower Drug Costs Now Act of 2019
S. 2543, Prescription Drug Pricing Act of 2019
H.R. 19, Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Coronavirus impact and response, drug pricing, drug shortages, pre-approval information exchange.
S. 1895, Lower Health Care Costs Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123)
H.R. 6201. Families First Coronavirus Response Act (P.L. 116-127)
H.R. 748, CARES Act (P.L. 116-136)
H.R. 6800, The Heroes Act
H.R., Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139)
H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act;
H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief,
and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 28, 2020.
Original Filing: 301225467.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization, COVID-19
H.R. 3, Lower Drug Costs Now Act of 2019
S. 2543, Prescription Drug Pricing Act of 2019
H.R. 19, Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Coronavirus impact and response, drug pricing, drug shortages, pre-approval information exchange.
S. 1895, Lower Health Care Costs Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123)
H.R. 6201. Families First Coronavirus Response Act (P.L. 116-127)
H.R. 748, CARES Act (P.L. 116-136)
H.R. 6800, The Heroes Act
H.R., Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301199484.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization, COVID-19
H.R. 3, Lower Drug Costs Now Act of 2019
S. 2543, Prescription Drug Pricing Act of 2019
H.R. 19, Lower Costs, More Cures Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Coronavirus impact and response, drug pricing, drug shortages, pre-approval information exchange.
S. 1895, Lower Health Care Costs Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123)
H.R. 6201. Families First Coronavirus Response Act (P.L. 116-127)
H.R. 748, CARES Act (P.L. 116-136)
H.R. 6800, The Heroes Act
H.R., Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139)
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q12020 on April 20, 2020
Original Filing: 301177161.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization; submit comments to CMS on the MA and Part Annual Rate Notice, and the ACA NBPP.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence on lowering health care costs, support to changes in 42 C.F.R., dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr),submit comments to the FDA on the draft importation guidance, and issues related to coronavirus relief.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 17, 2020.
Original Filing: 301170299.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, Part D, electronic prescribing, prior authorization and electronic prior authorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence on lowering health care costs, support to changes in 42 C.F.R., dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr) and issues related to coronavirus relief.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 17, 2020.
Original Filing: 301108778.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Sent Dec. 16th letter to Reps. DeGette and Upton on 21st Century Cures 2.0. Submitted comments to HHS on OIG/revisions to safe harbors under the anti-kickback statute.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr) and issues related to H.R. 3, Lower Drug Costs Now Act of 2019 and S. 2543 Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301075341.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Sent letter to Senate Finance Committee Chair and Ranking Member submiting comments on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019, Disseminated information on H.R. 2026 - "Pharmaceutical Information Exchange Act"
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 23, 2019.
Original Filing: 301059326.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 18, 2019.
Original Filing: 301028966.xml
Lobbying Issues
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization.
Meeting with the Department of Health and Human services on proposal to restrict the use of rebates under Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 20, 2019.
Original Filing: 301011182.xml
Lobbying Issues
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Meeting with the Centers for Medicare and Medicaid Services regarding the medication therapy management program under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill.
Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q32018 on Nov. 9, 2018
Original Filing: 301000303.xml
Lobbying Issues
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint.
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill.
Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
Academy of Managed Care Pharmacy filed a lobbying registration on Oct. 17, 2018 for in-house lobbying efforts, effective Sept. 28, 2018.
Original Filing: 300986711.xml
Issue(s) they said they’d lobby about: Issues related to Medicare Part D, opioids, Medicare Part B, value-based contracting, payment for pharmacist services, biosimilars, FDA issues, drug pricing .
3rd Quarter, 2018
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q32018 on Oct. 17, 2018
Original Filing: 300986715.xml
Lobbying Issues
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint.
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill.
Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 12, 2018.
Original Filing: 300984927.xml
Lobbying Issues
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint.
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill.
Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q22018 on July 16, 2018
Original Filing: 300965348.xml
Lobbying Issues
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 12, 2018.
Original Filing: 300964355.xml
Lobbying Issues
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 19, 2018.
Original Filing: 300951462.xml
Lobbying Issues
Submitted comments to CMS on Medicare Advantage and Medicare Part D Rule, joined other stakeholders in letter HHS OIG in support of a safe harbor provision for that would encourage development of value-based contracts for the Medicare and Medicaid populations,submitted comments to CMS on the 2019 draft Call letter and submitted letter to Rep. Schweikert in support of H.R. 4148 concerning standardizing electronic prior authorization for Medicare beneficiaries.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 12, 2018.
Original Filing: 300923480.xml
Lobbying Issues
Submitted comments to CMMI on recommendations to transform Medicare and Medicaid Programs
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 13, 2017.
Original Filing: 300903851.xml
Lobbying Issues
Submitted comments to CMS on the CY 2018 updates to the Quality Payment Program. Submitted comments to CMS on the Draft CY 2018 Medicare Part B Physician Fee Schedule.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Letter submitted to the Honorable Kevin Brady as part of the National Quality Forum (NQF) coalition in support of continued funding for the NQF as part of the funding for Medicare.
Participated in a lobby days program as a member of the Alliance for a Stronger FDA and met with Senate members of appropriations committee to request adequate funding for the FDA.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 18, 2017.
Original Filing: 300887880.xml
Lobbying Issues
Comments submitted advocating for transformation and modernization of the Medicare Part D program.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability,
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 18, 2017.
Original Filing: 300868065.xml
Lobbying Issues
MTM comprehensive medication review standardization and testing and implementing and adopting SNOMED CT codes for MTM and comments on the 2018 Draft Medicare Call letter
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Supporting the dissemination of pharmacoeconomic information and urging Congress to continue its efforts against allowing substandard and dangerous counterfeit drugs to be imported across U.S. borders
Agencies Lobbied
U.S. Senate
Lobbying Issues
Urging SAMHSA and Congress to take steps to modernize the underlying statute for 42 C.F.R. Part 2 by making it consistent with HIPAA - currently substance abuse records are not allowed to be shared without specific consent
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 13, 2017.
Original Filing: 300845763.xml
Lobbying Issues
21st century cures,Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D issues concerning managed care pharmacy, comments to FDA on BsUFA II reauthorization citing a need for biosimilars education and post market surveillance, comments in support of 21st Century Cures Act to support Section 3037 - Health care economic information, comments to CMS regarding implementation of CARA - P.L. 114-198, and comments to CMS on Medicare Part D MTM program. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records. Meeting with OMB to discuss impact of the SAMSHA pending final rule on confidentiality of substance abuse records (42 CFR Part 2).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 13, 2016.
Original Filing: 300827610.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 15, 2016.
Original Filing: 300810159.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Medicare Part B Drug Demonstration Projects, Senate Innovations Initiative and Medication Therapy Management (MTM)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 15, 2016.
Original Filing: 300791780.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 13, 2016.
Original Filing: 300771462.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 16, 2015.
Original Filing: 300754907.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 15, 2015.
Original Filing: 300735705.xml
Lobbying Issues
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries,Biosimilar naming, Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 4, 2015.
Original Filing: 300712560.xml
Lobbying Issues
21st century cures, Medicare Part D lock in programs, Biosimilar naming, Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 15, 2015.
Original Filing: 300696649.xml
Lobbying Issues
Support for increased FDA funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area or among a medically underserved population - HR 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q32014 on Oct. 17, 2014
Original Filing: 300679125.xml
Lobbying Issues
Support for increased FDA funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area of among a medically underserved population - H.R. 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 18, 2014.
Original Filing: 300661627.xml
Lobbying Issues
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled
substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for increased FDA funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 16, 2014.
Original Filing: 300638014.xml
Lobbying Issues
Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Generic Labeling - advocating that FDA ensure safety in generic drug labeling by requesting that FDA change its proposed rule
Agencies Lobbied
Food & Drug Administration (FDA)
4th Quarter, 2013
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 13, 2014.
Original Filing: 300613362.xml
Lobbying Issues
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 11, 2013.
Original Filing: 300592516.xml
Lobbying Issues
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy --
S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced security in the drug distribution chain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 17, 2013.
Original Filing: 300574495.xml
Lobbying Issues
S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced security in the drug distribution chain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support for increased FDA funding
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300561171.xml
Lobbying Issues
S 77/S 117/HR 1102 - legislation that would require or allow the federal government to negotiate prescription drug prices for Medicare Part D plan sponsors; Proposals to expand Medicaid "best price" rebates to dual eligibles in Medicare Part D; proposal repeal requirement that Part D plan sponsors cover all or substantially all drugs in therapeutic classes of concern; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 214 - legislation that would presume illegal patent settlement agreements between brand-name and generic manufacturers in which the brand-name manufacturer compensates the generic manufacturer to delay market entry of a generic drug; proposal to shorten the length of data exclusivity for reference biologic products from 12 years to 7 years; proposals to allow importation of prescription drugs from foreign countries
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Senate amendment 67 to HR 933 - amendment that would restrict government employee attendance at meetings and conferences to no more than 25 employees
4th Quarter, 2012
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 18, 2013.
Original Filing: 300535186.xml
Lobbying Issues
HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverageHR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 5973/S 2323 - appropriations legislation covering the U.S. Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product;HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300516571.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverageHR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2012
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300492211.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverageHR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2012
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 13, 2012.
Original Filing: 300460338.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D
S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors
HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal governmentHR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications
HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D
HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts.
HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors.
Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 2112 - appropriations legislation covering the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product
HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee actS 296 and HR 2245 - legislation that would address shortages of prescription drugs
HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA
HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program
HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs
HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2011
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300447249.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D
S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors
HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal governmentHR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D.
HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications
Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 2112 - appropriations legislation covering the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product.
HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee actS 296 and HR 2245 - legislation that would address shortages of prescription drugs
HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA.
HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2011
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 12, 2011.
Original Filing: 300412450.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D
S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors
HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal governmentHR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D.
HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications
Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 2112 - appropriations legislation covering the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product.
HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee actS 296 and HR 2245 - legislation that would address shortages of prescription drugs
HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA.
HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2011
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 18, 2011.
Original Filing: 300392281.xml
Lobbying Issues
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D
S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors
HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress.
Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 2112 - appropriations legislation covering the Food and Drug Administration. Also discussed topic of FDA funding generally with Senate staff.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product.
HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1893 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2011
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 19, 2011.
Original Filing: 300370029.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit: modifying current Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse; legislation that would expand the current medication therapy management program in Part D (S 274/HR 891)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation relating to pharmacy issues and the professional role of pharmacists, legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Granting independent pharmacists collective bargaining rights/antitrust exemption
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2010
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300352112.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit; modifying current Medicare Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased funding for comparative effectiveness research; legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation relating to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation that would grant independent pharmacists collective bargaining rights/antitrust exemption
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2010
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300323954.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit; modifying current Medicare Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
increased funding for comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation relating to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for such programs; legislation relating to the importation of prescription drugs; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally; legislation regulating pharmacy benefit managers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation that would grant independent pharmacists collective bargaining rights/antitrust exemption.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2010
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 19, 2010.
Original Filing: 300294180.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit; adjustment to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation relating to to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for said programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation that would grant independent pharmacists collective bargaining rights
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2010
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300268991.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustment to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; legislation related to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation that would grant independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2009
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300246984.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustment to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation reslating to health information technology and electronic prescribing; appropriations for U.S. Food and Drug Administrations and the Agency for Healthcare Research and Quality.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists; legislation related to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to setlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation that would grant independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2009
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300214699.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustment to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effetiveness research; legislation relations to health information technology and elecrtonic prescribing; appropriations for U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2009
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q22009 on Aug. 6, 2009
Original Filing: 300196807.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2009
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 20, 2009.
Original Filing: 300189919.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for FDA approval of follow-on biologic products; electronic prescribing of controlled substances and generally; regulation of online pharamcies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2009
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q12009 on Aug. 6, 2009
Original Filing: 300196806.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescripion drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2009
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 22, 2009.
Original Filing: 300166314.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescripion drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2008
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q42008 on Aug. 6, 2009
Original Filing: 300196805.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances and generally, regulation of online pharmacies, importation of prescription drugs, federal funding for academic detailing programs, promotion of the use of generic drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to perform comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2008
In Q4, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Jan. 21, 2009.
Original Filing: 300130848.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances and generally, regulation of online pharmacies, importation of prescription drugs, federal funding for academic detailing programs, promotion of the use of generic drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to perform comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2008
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q32008 on Aug. 6, 2009
Original Filing: 300196804.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit (Medicare Improvements for Patients and Providers Act of 2008).
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, eletronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2008
In Q3, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300105832.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit (Medicare Improvements for Patients and Providers Act of 2008).
Adjustments to Medicaid prescription drug reimbursement rates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, eletronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent pharmacists collective bargaining rights
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2008
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q22008 on Aug. 6, 2009
Original Filing: 300196803.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer's price).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent and community pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2008
In Q2, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on July 17, 2008.
Original Filing: 300068618.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit.
Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer's price).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent and community pharmacists collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2008
ACADEMY OF MANAGED CARE PHARMACY amended a lobbying report for in-house lobbying in Q12008 on Aug. 6, 2009
Original Filing: 300196802.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustments to Medicare prescription drug reimbursement rates (calculation of average manufacturer's price).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, Electronic prescribing of controlled substances, Regulation of online pharmacies, Importation of prescription drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent and community pharmacies collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2008
In Q1, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on April 11, 2008.
Original Filing: 300035614.xml
Lobbying Issues
Proposed changes to the Medicare Part D prescription drug benefit.
Adjustments to Medicare prescription drug reimbursement rates (calculation of average manufacturer's price).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, Electronic prescribing of controlled substances, Regulation of online pharmacies, Importation of prescription drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation granting independent and community pharmacies collective bargaining rights.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
0th Quarter, 2007
In MM, ACADEMY OF MANAGED CARE PHARMACY had in-house lobbyists. The report was filed on Aug. 2, 2007.
Original Filing: 200044656.xml
Lobbying Issues
Proposed changes to Medicare Part D prescription drug benefit.
Lobbying Issues
Food and Drug Administration reform efforts: expansion of post-market surveillance programs for prescription drugs; post-market risk management; additional monitoring of direct-to-consumer advertisements for prescription drugs; additional agency funding.
Lobbying Issues
Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer price).
Lobbying Issues
Legislation relating to "follow-on" biologic pharmaceuticals.
Lobbying Issues
Legislation relating to authorized generic prescription drugs.
Lobbying Issues
Importation of prescription drugs/counterfeit drugs.
Lobbying Issues
Federal regulation of the practice of pharmacy compounding,
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...